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Summary
We discovered that monoclonal antibodies (mAbs) specific to human b2-microglobulin (b2M) induce apoptosis in vitro and
were therapeutic inmousemodels of myeloma and other hematological tumor cells. Cell death occurred rapidly, without the
need for exogenous immunological effectormechanisms. ThemAbs induced cell death via recruitingMHC class I molecules
to lipid rafts and activating Lyn and PLCg2, leading to activated JNK and inhibited PI3K/Akt and ERK, compromised
mitochondrial integrity, and caspase-9-dependent cascade activation. Although the expression of b2M on normal hemato-
poietic cells is a potential safety concern, the mAbs were selective to tumor-transformed cells and did not induce apoptosis
of normal cells. Therefore, such mAbs offer the potential for a therapeutic approach to hematological malignancies.Introduction
Within the past decade, monoclonal antibodies (mAbs) have
broadened the therapeutic armamentarium in oncology (Lin
et al., 2005). Hematological malignancies are recognized as
particularly promising targets, reflected by the current list of
FDA-approved mAbs that are used to treat patients (Owaidah
and Aljurf, 2002; Reff et al., 2002). The mAbs exert their in vivo
effect largely through the immunological effector mechanisms
of complement-mediated lysis and/or antibody-dependent
cell-mediated cytotoxicity (ADCC). Thus, their efficacy is depen-
dent on intact immunological mechanisms in the treated
patients. Although the molecules targeted by these mAbs are
usually widely expressed on normal lymphoid and myeloid cells
in addition to malignant cells, the therapeutic efficacy of these
mAbs has been promising (Lin et al., 2005; Owaidah and Aljurf,
2002; Reff et al., 2002). Nevertheless, it would be useful to de-
velop mAbs with the capability to kill tumor cells, but not normal
cells, without complement and ADCC.
b2M is an 11.6 kDa nonglycosylated polypeptide composed
of 100 amino acids. It is part of themajor histocompatibility com-
plex (MHC) class I molecule on the cell surface of nucleatedCANCER CELL 10, 295–307, OCTOBER 2006 ª2006 ELSEVIER INC. DOcells. Its best characterized function is to interact with and sta-
bilize the tertiary structure of the MHC class I a chain (Bjorkman
and Burmeister, 1994). Because it is noncovalently associated
with the a chain and has no direct attachment to the cell mem-
brane, b2M on the cell surface can exchange with free b2M pres-
ent in serum-containing medium (Strominger, 2002). Free b2M is
found in body fluids under physiological conditions as a result of
intracellular release. Elevated levels of serum b2M are present in
hematological malignancies, including lymphomas (Cooper and
Plesner, 1980), leukemias (Molica et al., 1999; Shvidel et al.,
1996), and multiple myeloma (Barlogie et al., 1999; Bataille
et al., 1983), and correlate with a poor prognosis regardless of
a patient’s renal function (Alexanian et al., 1985; Bataille et al.,
1983). This observation suggests an important, yet unidentified,
role of this protein in these malignancies. While examining the
effects of b2M on myeloma cells, we made an exciting discov-
ery; namely, that mAbs against b2M have a remarkably strong
apoptotic effect on myeloma cells and on other hematological
tumor cells. In this report, we demonstrate potent tumoricidal
activity of b2M-specific mAbs both in vitro and in animal models
and elucidate the apoptotic and signaling pathways induced by
b2M-specific mAbs in tumor cells.S I G N I F I C A N C E
Monoclonal antibodies (mAbs) are currently andhavebeen successfully used to treat cancers. This report describes findings thatmAbs
specific to human b2-microglobulin (b2M) exhibited potent in vitro tumoricidal activity on several myeloma, lymphoma, and leukemia
cell lines and primary myeloma cells from patients, and were therapeutic in vivo in xenograft mouse models of myeloma and other
tumors. We present preclinical evidence of their low toxicity on the human hematopoietic system, demonstrate the efficacy of the
mAbs as a single agent to treat established tumors in animal models, and elucidate apoptotic and signaling pathways induced by
the mAbs. These mAbs offer the potential for a therapeutic approach to hematological malignancies.I 10.1016/j.ccr.2006.08.025 295
A R T I C L EFigure 1. In vitro tumoricidal activity of b2M-specific mAbs
A: Annexin V-staining, and B, TUNEL assay for detection of apoptosis in myeloma cells in cultures for 48 hr with medium or with the addition of 100 mg/ml
b2M-specific mAb B2, HLA-ABC-specific mAb LY5.1, or mouse IgG1. C: Dose-dependent (in a 48 hr culture), and D, time-dependent response of b2M-specific
mAb-induced apoptosis (50 mg/ml mAbs) in myeloma cells induced by B2, LY5.1, and mouse IgG1. Results of four independent experiments using myeloma
cell line RPMI-8226 are shown. Similar results were obtained with other myeloma cell lines. E: Induction of apoptosis, detected by Annexin V binding assay, in
primary myeloma cells from eight patients (P1–P8) with multiple myeloma in medium or induced by 50 mg/ml B2 or D1 b2M-specific mAbs in 24 hr cultures.
Results of three experiments are shown. Similar results were obtained with TUNEL assay. *p < 0.05; **p < 0.01. Error bars = SEM.Results
Tumoricidal activity of b2M-specific antibodies
In our study examining the effects of b2M on myeloma cells,
a commercially available mAb against human b2M (clone B2,
mouse IgG1; supplied in PBS without sodium azide from Sero-
tec Ltd., Oxford, UK) (Liabeuf et al., 1981) was used in the block-
ing experiments. To our surprise, B2 mAb induced apoptosis in
a large percentage of myeloma cells (p < 0.01, compared with
medium control), evident by both Annexin V binding (Figure 1A)
and TUNEL assays (Figure 1B). Control mAbs LY5.1 (IgG1) or
W6/32 (IgG2a; data not shown) specific for human leukocyte an-
tigen (HLA-ABC)molecule, purifiedmouse IgG (data not shown),
or IgG1 had no effect. The apoptotic response was dose-
(Figure 1C) and time-dependent (Figure 1D); significant induc-
tion of apoptosis in myeloma cells was already seen at a low
mAb concentration as 12.5 mg/ml in a 24 hr culture (p < 0.05,
compared with medium control). The apoptotic effect of the
mAb was not counteracted by myeloma cell-survival cytokines
such as IL-6 or insulin-like growth factor-I (data not shown).
The tumoricidal activity was not restricted to this mAb; similar
results were obtained with other commercial antibodies, such
asmAb BBM.1 (ATCC, Rockville, MD) and a polyclonal antibody
(MP Biomedicals, Inc., St. Louis, MO), although their apoptotic
effects differed (data not shown).
We generated a panel of mouse mAbs against human b2M by
immunizing Balb/c mice with purified b2M, fusing spleen296lymphocytes with SP2/0myeloma cells, screening, and expand-
ing hybridomas. After several rounds of fusion and screening,
more than 20 hybridomas producing significant amounts of
mAbs against human b2M were obtained. Four of these clones
were selected because they secreted IgG1-isotype mAbs; this
is the same isotype as B2 mAb. Two of the mAbs, designated
D1 and E6, were strong apoptosis inducers (Table 1), whereas
the other two had weak tumoricidal activity (data not shown).
Therefore, D1 and E6, together with B2, were used to test for in-
duction of tumor cell apoptosis with a panel of 16 surface b2M/
HLA-ABC+ and 2 b2M/HLA-ABC
–/low cell lines of hematological
malignancies, including Burkitt’s lymphoma, non-Hodgkin’s
lymphoma, mantle cell lymphoma, T cell leukemia, acute and
chronic myelogenous leukemias, and multiple myeloma. The
mAbs killed between 44% to 90% of cells from 16 b2M/HLA-
ABC+ tumor cell lines. No or weak effects were observed on
b2M/HLA-ABC
–/low cell lines Daudi and K562 cells. However,
statistical analysis revealed no linear correlation between killing
efficiency and the level of b2M/HLA-ABC expression in
b2M/HLA-ABC
+ tumor cell lines. In these experiments, the con-
trol mAbs LY5.1 and W6/32 and purified mouse IgG1 were
tested in parallel, and no significant apoptosis was observed
(data not shown).
Melphalan and dexamethasone are two commonly used che-
motherapy drugs for myeloma. Myeloma cell lines ARP-1 and
MM.1S are sensitive to dexamethasone, and RPMI-8226 and
U266 are sensitive to melphalan. We compared the capacityCANCER CELL OCTOBER 2006
A R T I C L Eof the mAbs with these chemotherapy agents to kill myeloma
cells. As potent as melphalan, the mAbs, especially D1 (p <
0.05, compared with dexamethasone), had stronger tumoricidal
activity than dexamethasone on sensitive cell lines (see Fig-
ure S1 in the Supplemental Data), even though higher drug con-
centrations were used (10–20 mM) (Georgii-Hemming et al.,
1996; Hardin et al., 1994). These mAbs efficiently killed dexa-
methasone-sensitive MM.1S and dexamethasone-resistant
MM.1R, suggesting that chemotherapy-refractory myeloma is
potentially sensitive to these mAbs.
We investigated whether the b2M-specific mAbs would also
be active on freshly isolated primary myeloma cells from pa-
tients. Purified myeloma plasma cells obtained from bone mar-
row aspirates of eight multiple myeloma patients were efficiently
and uniformly killed by themAbs (p < 0.05 to p < 0.01; Figure 1E).
Reduced cell viability was already observed after 4 hr of treat-
ment. After 24 hr only about 10% to 30%of cells remained viable
in cultures with the addition of themAbs, while the viability of the
cells in control medium was 60% to 80%. The control mAb
LY5.1 and mouse IgG1 had no effect on the primary myeloma
cells. As noted before (Yi et al., 1997), all of these primary mye-
loma cells expressed surface b2M/HLA-ABCmolecules at levels
equal to those found on myeloma cell lines (see Figure 3A).
Since we have shown that bone marrow stromal cells such as
osteoclasts promote growth and protect myeloma cells from
apoptosis in vitro (Yaccoby et al., 2004), we studied the effect
of the mAbs on myeloma cell survival in a coculture with osteo-
clasts. Primary myeloma cells from patients were isolated, and
after 48 hr culture in the presence of the mAbs, fewer viable
(Figure 2A) and more apoptotic myeloma cells (Figure 2B)
were recovered from the cocultures (p < 0.05, compared with
controls). Interestingly, the mAbs did not affect the viability of
osteoclasts measured by the 3-(4,5-dimethylthiazol-2-yl)-2,









Name Tumor type MFI B2 D1 E6
ARK multiple myeloma 2037 76 84 80
APR-1 multiple myeloma 1872 61 70 64
CAG multiple myeloma 1120 65 70 65
MM.1R multiple myeloma 1276 70 90 83
MM.1S multiple myeloma 1590 73 86 80
RPMI-8226 multiple myeloma 1584 64 66 62
U266 multiple myeloma 2166 63 80 75
XG-1 multiple myeloma 1560 56 64 60
BJAB Burkitt’s lymphoma 2319 53 56 54
CA46 Burkitt’s lymphoma 2289 67 76 76
Raji Burkitt’s lymphoma 1245 45 53 50
Mino mantle cell lymphoma 1936 60 66 56
Granta 519 mantle cell lymphoma 1860 52 49 44
SP53 mantle cell lymphoma 2383 50 44 39
Jurkat T cell leukemia 873 44 53 48
KG1 myelogenous leukemia 1002 55 57 60
K562 myelogenous leukemia 60 15 20 19
Daudi B cell lymphoma 7 8 7 9
aExpressed as mean fluorescence intensity (MFI).
bShown are percentages of Annexin V-positive apoptotic cells at 48 hr cul-
tures, which were confirmed by TUNEL assay. The percentages of apoptotic
cells in medium alone were 3% to 20% (median: 10%). Each number repre-
sents the average of three to five independent experiments.CANCER CELL OCTOBER 20065-diphenyltetrazolium bromide (MTT) assay (Figure 2C), which
suggested that b2M-specific mAbs selectively killed malignant,
but not normal, cells.
To confirm the findings that mAbs could selectively kill mye-
loma cells without damaging normal hematopoietic cells, a
coculture of myeloma cells (0.2 3 106 cells/ml) with peripheral
bloodmononuclear cells (PBMCs) (13 106 cells/ml) fromhealthy
donors was employed, which partially mimics the in vivo situa-
tion in which myeloma cells are surrounded and outnumbered
by b2M/MHC class I-expressing normal cells. To minimize T
cell activation induced by myeloma cells, 0.4 mm pore size
Transwell inserts were used to separate myeloma cells from
PBMCs. Cultures of (1) PBMCs or myeloma cells alone and (2)
cocultures with medium only or with the addition of the control
mAb LY5.1 or mouse IgG1 served as controls. As shown in
Figure 2D, b2M-specific mAbs killed myeloma cells with the
same efficacy irrespective of whether the (co)cultures contained
PBMCs. No cell apoptosis was induced in PBMCs or in lympho-
cyte subsets, such as CD3+ T cells, CD19+ B cells, or CD16+ NK
cells (Figure 2E). As this is an important issue for future clinical
application, we tested the mAbs on purified blood lymphocytes,
both resting and phytohemagglutinin-activated (Figure 2F), and
on purified bone marrow CD34+ stem cells (Figure 2G) from
healthy individuals. Both types of cells were resistant to b2M-
specificmAb-mediated apoptosis. Similar results were obtained
with resting and lipopolysaccharide-activated B cells, purified
fromperipheral blood of healthy donors using CD19-specific an-
tibody-coated magnetic beads (data not shown). Control mAb
LY5.1 (data not shown) or mouse IgG1 (Figure 2) did not induce
apoptosis in myeloma or normal cells. Taken together, these
findings clearly demonstrated the ability of the mAbs to specif-
ically target and kill myeloma cells in the presence of normal
hematopoietic cells without damaging the normal cells, and
suggested that the potential hematological side effects of the
mAbs may be minimal.
Selectivity andmechanism of b2M-specificmAb-induced
cell death
As b2M and HLA-ABC molecules are expressed on nucleated
cells, we compared the expression levels of these molecules
on myeloma tumor cells and normal blood cells. As shown in
Figure 3A, myeloma cells expressed significantly higher levels
of b2M and HLA-ABC than normal peripheral blood monocytes
and lymphocytes (p < 0.05). Furthermore, immunohistochemical
staining of patients’ bone marrow biopsies demonstrated that
myeloma plasma cells, but not normal hematopoietic cells,
were stained by antibody against b2M (Figure 3B), which again
indicated that myeloma cells express higher levels of the mole-
cule than other normal marrow cells. Normal marrow cells also
express low levels of these molecules that were not detected
by the insensitive method. These results suggested that mye-
loma plasma cells may be a preferential target for the mAbs.
We next investigated whether the presence of soluble b2M in
medium would block the apoptotic effects of b2M-specific
mAbs on tumor cells. In these experiments, b2M-specific
mAbs (50 mg/ml; molecular weight of IgG: 150 kDa) were prein-
cubated for 30 min with much higher molar concentrations of
b2M (50–100 mg/ml; molecular weight of b2M: 11.6 kDa) before
tumor cells were added to the cultures and incubated for an-
other 48 hr. The apoptosis-inducing effects of the mAbs were
reduced, but not blocked (Figure 3C). Further experiments297
A R T I C L EFigure 2. Killing of myeloma, but not normal hematopoietic cells, by b2M-specific mAbs
Effect of b2M-specific mAbs on primary myeloma cells and normal osteoclasts in their cocultures. A: Viable myeloma cells; B, percentage of apoptotic my-
eloma cells; andC, viability of osteoclasts in the cocultures with the addition of 50 mg/ml B2 mAb or mouse IgG1 for 48 hr. Cocultures with medium alone served
as control. Details are described in Experimental Procedures. Effect of b2M-specific mAbs on myeloma cell lines and normal PBMCs in their cocultures: D, Ap-
optotic myeloma cells, and E, apoptotic PBMCs and lymphocyte subsets in their cocultures, in which PBMCs (106/ml) were seeded on wells and myeloma cells
(0.2 3 106/ml) were placed on inserts. b2M-specific mAbs (50 mg/ml) were added to the wells and incubated for 48 hr. Cells were cultured in RPMI-1640 sup-
plemented with 10% fetal calf serum. No lymphocyte growth factors were added. After culture, cells were recovered and apoptotic cells were detected
using the Annexin V binding assay. To examine apoptotic lymphocyte subsets, PE-conjugated CD3-, CD19-, and CD16-specific antibodies were used to iden-
tify the subsets, while FITC-conjugated Annexin V was used to identify apoptotic cells. Shown are the results of three experiments using D1 mAb on MM.1S.
Similar results were obtained with ARP-1 and B2 mAb. F: Detection of apoptosis in lymphocytes (Lym; both resting and PHA-activated), and G, bone mar-
row-derived stem cells in cultures with the mAbs. Experiments were performed with 50 mg/ml B2 or D1 mAbs in 48 hr cultures. Results of four independent ex-
periments are shown. *p < 0.05. Error bars = SEM.showed that, under such conditions (50 mg/ml b2M-specific
mAbs preincubated with 50–100 mg/ml b2M for 30 min), the
b2M-specific mAbs could still bind to surface b2M (Figure 3D),
although to a lesser extent. These results indicated that the
mAbs have a higher affinity for surface-bound rather than solu-
ble b2M and may explain why b2M-specific mAbs are tumorici-
dal despite the presence of high concentrations of soluble b2M.
To further verify that cell surface b2M was the target, small in-
terfering RNA (siRNA) for b2Mgenewas synthesized and used to
knockdown b2M expression in myeloma cells. After extensive
preliminary studies to optimize the dose of siRNA and transfec-
tion, we were able to achieve 70% to 80% reduction of surface
b2M (and HLA-ABC; data not shown) protein expression on my-
eloma cells on day 3 after transfection with b2M-specific siRNA
(Figure 3E), which remained at low levels for up to 7 days (data
not shown). Detection of b2M mRNA by RT-PCR confirmed this
result (data not shown). This treatment was specific for b2M, as
surface expression of MHC class II (HLA-DR) and CD38 (data298not shown) remained unchanged. It is evident that knockdown
of surface b2M/MHC class I on myeloma cells rendered the cells
resistant to b2M-specific mAb-induced apoptosis, whereas
mock control and control siRNA had no effect (Figure 3E). As ex-
pected (Caplen and Mousses, 2003), all of these treatments or
transfections killed a small percentage of the cells.
It is conceivable that b2M-specific mAbs triggered intracellu-
lar signaling by binding to surface b2M/MHC class I molecules,
leading to tumor cell apoptosis. Therefore, we examined the lo-
calization and density of b2M/MHC class I molecules and their
complexes with b2M-specific mAbs in tumor cells by immuno-
fluorescence staining and flow cytometry analysis. As shown
in Figure 3F, cells recovered from 0 hr of culture (incubating cells
with b2M-specific mAbs on ice for 20 min) displayed surface
staining by b2M-specific mAbs. Cells recovered from cultures
for 6 to 24 hr at 37C displayed a gradual intracellular staining,
demonstrating internalization of b2M-specific mAb-MHC class
I complexes. By 48 hr, mainly apoptotic bodies were seen. InCANCER CELL OCTOBER 2006
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molecules was seen on tumor cells during this time frame after
treatment with b2M-specific mAbs (Figure 3G; p < 0.05 to p <
0.01, compared with the starting level), while surfaceMHC class
II (HLA-DR) expressionwas not affected (data not shown). These
results indicate that binding of b2M-specificmAbs to cell surface
b2M/MHCclass Imolecules led to internalization and downregu-
lation of these molecules, which might be responsible for induc-
tion of apoptosis in treated cells.
Various types of apoptosis, such as receptor-mediated or
stress-induced apoptosis, depend on the activation of cas-
pases. To investigate whether and which caspase cascades
participated in b2M-specific mAb-induced apoptosis, activation
and cleavage of caspase-9, -8, -3, -7, and subsequent cleavage
of PARP were investigated by western blotting with specific an-
tibodies. Treatment with b2M-specific mAbs resulted in activa-
tion and cleavage of caspase-9, -3, -7, and PARP, but not cas-
pase-8, in myeloma cells (Figure 4A). Caspase (-9, -3) and PARP
activation (Figure 4B) and cell apoptosis (Figure 4C) were
inhibited by the pan-caspase inhibitor Z-VAD and caspase-9 in-
hibitor Z-LEHD, but not by caspase-8 inhibitor Z-IETD (data not
shown). Since these results indicated that the intrinsic apoptosis
pathway was utilized, we next investigated the involvement of
mitochondria and its associated proapoptosis and antiapopto-
sis proteins. b2M-specific mAbs upregulated the expression of
proapoptotic proteins Bad and Bax (Figure 4D). While the ex-
pression of antiapoptotic proteins Bcl-2 and Bcl-xL remained
unchanged, the level of phosphorylated Bcl-2 (pBcl-2) was in-
creased and that of phosphorylated Bad (pBad) was decreased;
this favors the induction of apoptosis due to increased perme-
ability of mitochondria (Srivastava et al., 1998; Zha et al., 1996),
leading to release of cytochrome c into cytosol. Indeed, at 24
hr and onward, cytosolic cytochrome c (cCyto C) was detected
in b2M-specific mAb-treated tumor cells, whereas the amount
of total cytochrome c (tCyto C) remained the same (Figure 4D).
In addition to caspase cascades,wealso examined the signal-
ing pathways inducedby b2M-specificmAbs.We focused on the
mitogen-activated protein kinase andPI3K/Akt pathways, which
are essential for cell survival and growth. As shown in Figure 4E,
b2M-specific mAb treatment increased the level of phosphory-
lated JNK (pJNK) and decreased those of pAkt and pERK. These
effectswere observed as early as 15min after the treatment. By 2
hr, pAkt and pERK were undetectable. The levels of nonphos-
phorylated JNK, Akt, and ERK remained stable. Hence, b2M-
specific mAbs activated the JNK pathway and inhibited PI3K/
Akt and ERK pathways in treated cells, all of which could lead
to induction of apoptosis (Franke et al., 1997; Xia et al., 1995).
On the other hand, normal cells, such as B cells, expressed
higher levels of pJNK and lower levels of pAkt and pERK, com-
pared with myeloma cells, which remained unchanged after
the treatmentwith themAbs (Figure S2). To verify the importance
of JNK activation in the induction of apoptosis in myeloma cells,
we used a specific JNK inhibitor (JNK inhibitor II or SP600125
[Bennett et al., 2001]; Calbiochem-Novabiochem, La Jolla, CA).
As complete inhibition of JNK activity would lead to apoptosis,
we titrated and used a low dose (5 mM) of the inhibitor to partially
inhibit JNK activity (Figure 4F) without affecting cell viability
(Figure 4G). Our results showed that JNK inhibitor II almost
completely abrogated apoptosis induced by the mAbs.
Next, we attempted to find out how and through what linkers
b2M-specific mAbs induce signaling and apoptosis in myelomaCANCER CELL OCTOBER 2006cells. We identified lipid rafts because they are often involved in
cell signaling and apoptosis (Cherukuri et al., 2001; Harder,
2004), and previous studies suggested that theymay be respon-
sible for MHC class II and CD20mAb-induced apoptosis (Deans
et al., 2002; Nagy and Mooney, 2003). As MHC class II, but not
MHC class I, molecules were found in lipid rafts under physio-
logical conditions (Vogt et al., 2002), we hypothesized that
MHC class I relocation to lipid rafts and tyrosine kinases Lyn,
Syk, and phospholipase-Cg2 (PLCg2) may be involved in apo-
ptosis. These kinases have been previously shown to be
involved in MHC class I signaling (Skov et al., 1995, 1997). As
shown in Figure 5, MHC class I and Syk were detected in the
nonraft fractions (fractions 7–9) in untreated (not shown) and
mouse IgG1-treated myeloma cells (Figure 5A, left panels),
whereas in b2M-specific mAb-treated myeloma cells, MHC
class I, but not Syk, were also detected in the lipid rafts (fractions
2–5; Figure 5A, right panels). Lyn kinase was detected in the raft
fractions in both cells. Similar results were obtained with other
tumor cell lines (data not shown). However, in normal B cells
treated with or without the mAbs, MHC class I and the kinases
were detected only in the nonraft fractions (Figure 5B). These re-
sults indicated that Lyn is associated with the rafts, and that
MHC class I molecules were recruited to the lipid rafts in mye-
loma, but not in normal B cells, after treatment with the mAbs.
To confirm the involvement of lipid rafts in b2M-specific mAb-
induced apoptosis, we treated myeloma cells with methyl-b-
cyclodextrin (MCD), an agent that disrupts the structure of lipid
rafts in cell membrane (Anderson et al., 2000), and showed that
such a treatment abrogated apoptosis of the cells induced by
the mAbs (Figure 5C). Thus, these results provided strong
evidence for a crucial role of lipid rafts in b2M mAb-induced
apoptosis of tumor cells and a plausible explanation for the
selectivity of the mAbs.
An immunoprecipitation assay was used to confirm the inter-
actions of MHC class I with these kinases. Using antibodies
against MHC class I or the kinases, we showed that Lyn and
PLCg2 were physically associated with MHC class I in myeloma
cells after treatment with the mAbs, because immunoprecipita-
tion of MHC class I by mAb W6/32 coprecipitated Lyn and
PLCg2 in b2M-specific mAb-treated, but not in control (not
shown) or mouse IgG1-treated, myeloma cells, whereas Syk
was coprecipitated from both cells (Figure 5D). On the other
hand, immunoprecipitation of Lyn (Figure 5E) or PLCg2 (Fig-
ure 5F) kinases by their respective antibodies also coprecipi-
tated MHC class I in b2M-specific mAb-treated, but not in
control (not shown) or mouse IgG1-treated, myeloma cells. In
addition, western blot analysis showed that Lyn and PLCg2
were also phosphorylated in myeloma cells treated with b2M-
specific mAbs (Figure 5G). Taken together, these results dem-
onstrated that b2M/MHC class I on myeloma cells, after binding
to and being cross-linked by the mAbs, relocate to lipid rafts,
recruit, and activate Lyn and PLCg2 (but not Syk), which in
turn activate JNK and inhibit PI3K/Akt and ERK, and induce
apoptosis in myeloma cells (Figure S3).
In vivo therapeutic efficacy of b2M-specific mAbs
on established tumors
To test the in vivo efficacy of b2M-specific mAbs, we inoculated
severe combined immunodeficient (SCID) mice subcutaneously
with myeloma cell lines ARP-1 or MM.1S, Burkitt’s lymphoma
CA46, mantle cell lymphoma Granta 519, or acute myelogenous299
A R T I C L EFigure 3. Selectivity and mechanism of b2M-specific mAb-induced cell death
Expression and modulation of b2M and HLA-ABC on myeloma cells by b2M-specific mAbs.A: Flow cytometry examining the levels of surface b2M and HLA-ABC
molecules on myeloma cell lines (cell lines, n = 8), primary myeloma cells (MM cells, n = 6), and peripheral blood monocytes and lymphocytes from healthy
donors (n = 6). B: Staining for b2M in bone marrow biopsies of patients with myeloma by immunohistochemistry, which showed that only myeloma plasma cells,
but not normal hematopoietic cells, were stained by b2M-specific antibody. Scale bar, 20 mM. The insert shows a higher magnification (31200). C: Effects of
soluble b2M on b2M-specific mAb (B2 and D1)-induced apoptosis in myeloma cells, and D, effects of soluble b2M on b2M-specific mAb (B2) binding to surface
b2M. In these experiments, equal amounts, unless otherwise indicated, of b2M-specific mAbs and soluble b2M were preincubated to form immune complexes,
followed by the addition of myeloma cells (RPMI-8226; similar results were obtained with other cells) to the culture. Apoptosis was detected after cells were
cultured 24 hr at 37C by Annexin V binding assay, and surface staining was performed after 30 min incubation (on ice) by washing and incubating the cells
with FITC-conjugated antibody to mouse IgG. Cells preincubated with B2 mAb alone (B2) served as control for surface binding of the mAb. Representative
results of five independent experiments are shown. E: knockdown of surface b2M by specific siRNA abrogated b2M-specific mAb-induced apoptosis in mye-
loma cells. Shown are the results of two myeloma cell lines, MM.1S and ARP-1. The upper panels show the reduction of surface b2M, and middle panels show
the level of HLA-DR on myeloma cells detected by flow cytometry. Numbers above the histograms represent mean fluorescence intensity. Filled blue histo-
grams represent cells stained with control IgG, and open histograms show the levels of b2M expression on cells treated with mock siRNA (green) or transfected
with control siRNA (blue) or b2M-specific siRNA (red). Assay was performed 72 hr after transfection. Representative results of three independent experiments
are shown. The lower panels show percentages of apoptotic cells induced by b2M-specific mAb D1. Similar results were obtained with B2 mAb. In these300 CANCER CELL OCTOBER 2006
A R T I C L EFigure 4. b2M-specific mAb-induced apoptosis and signaling pathways
A: Western blot analysis showing protein levels of procaspase and cleaved caspases and PARP in b2M-specific mAb (D1)-treated myeloma cells. Inhibition of
caspase and PARP activation and processing (B) and apoptosis (C) is shown in b2M-specific mAb (D1)-treated myeloma cells with the addition of the pan-
caspase inhibitor Z-VAD or caspase-9 inhibitor Z-LEHD. Arrows indicate cleaved (c) caspases and PARP. D: Western blot analysis showing protein levels of
mitochondria-related proapoptotic and antiapoptotic proteins (cCyto C: cytosolic cytochrome c; tCyto C: total cytochrome c), and E, phosphorylated
(p) and nonphosphorylated JNK, Akt, and ERK in b2M-specific mAb (D1)-treated myeloma cells. Results obtained with D1 mAb on MM.1S myeloma cells
from one representative experiment of four performed are shown. Similar results are obtained with other b2M-specific mAbs on other myeloma cell lines as
well as primary myeloma cells. JNK inhibitor II abrogated (F) b2M-specific mAb-induced JNK activation, and G, apoptosis in myeloma cells. Medium control
contained DMSO. Results obtained with B2 or D1 mAb on MM.1S and/or ARP-1 myeloma cells from one representative experiment out of four performed are
shown. Similar results are obtained with other b2M-specific mAbs on this and other myeloma cell lines. *p < 0.05; **p < 0.01. Error bars = SEM.leukemia KG1, and SCID-humice (Yaccoby et al., 1998) with pri-
mary myeloma cells freshly isolated from patients, and moni-
tored tumor development. Sincewewanted to examine the ther-
apeutic potential of the mAbs as a single agent, treatment was
initiated when palpable tumors (R5 mm in diameter for SCID
mice or human M proteins reaching >50 mg/ml for SCID-hu
mice) developed and aftermurineNK cells were depleted. Treat-
ment with intraperitoneal injections of b2M-specific mAbs signif-
icantly reduced tumor burdens and retarded tumor growth,
measured as tumor volumes (upper panels; Figure 6A for mye-
loma and Figure 6B for other tumors, p < 0.05 to p < 0.01, com-
pared with controls) and/or levels of circulating M-proteins or
their light chains secreted by the myeloma cells in SCID mice
(Figures S4A and S4B for ARP-1 and MM.1S) or in SCID-
hu mice (primary MM, Figure 6A; p < 0.05 to p < 0.01, compared
with controls). Within the observation period, all control SCID
mice died, whereas 80% or more mAb-treated mice survived
with minimal tumor burdens (lower panels; Figure 6A forCANCER CELL OCTOBER 2006myeloma and Figure 6B for other tumors, p < 0.01, compared
with controls). Subcutaneous injections around the tumors of
the b2M-specific mAbs were even more effective in eradicating
the establishedmyeloma, including primary myeloma, andmost
of the treated mice were without detectable tumors at the end of
the study (data not shown). Together, the efficacy data are
promising and raise the possibility that such mAbs could be-
come useful and potent therapeutic agents for treating hemato-
logical malignancies.
b2M-specific mAbs caused no damage to human
hematopoiesis or b2M/HLA-A2-expressing
murine tissues and organs
SCID-hu and human b2M/HLA-A2-transgenic (A2-) mice were
utilized to examine the potential impact and toxicity of b2M-
specific mAbs on human hematopoiesis and human-like tissues
and organs. Tumor-free SCID-hu and A2-mice were treated in
the same way as tumor-bearing mice, and were sacrificed twoexperiments, cells were transfected with 400 nM siRNA, and 72 hr later, washed and incubated with 50 mg/ml b2M-specific mAbs for another 48 hr. Apoptosis
was detected by Annexin V binding assay. F: Immunofluorescence staining for extracellular and intracellular localization of b2M-specific (B2) mAb/MHC class I
molecules, visualized by FITC-conjugated antibody to mouse IgG1. Scale bar, 10 mM. G: Staining for surface HLA-ABC molecules on myeloma cells in cultures
(at different time points) with the addition of B2 or D1 b2M-specific mAbs. Medium or mouse IgG1 served as controls. Representative results of three indepen-
dent experiments are shown. *p < 0.05; **p < 0.01. Error bars = SEM.301
A R T I C L EFigure 5. Involvement of lipid rafts and kinases in b2M-specific mAb-induced apoptosis in tumor cells
Localization of MHC class I, Lyn, and Syk in lipid rafts (fractions 2–5) or nonraft fractions (fractions 7–9) in A, myeloma cells, or B, normal B cells after treatment
with mouse IgG1 (left panels) or b2M-specific mAbs (right panels). Lipid-raft fractions were confirmed by positive staining for caveolin-1, a raft-associated pro-
tein. C: Methyl-b-cyclodextrin (MCD) inhibits b2M-specific mAb-induced apoptosis of myeloma cells. In these experiments, cells were preincubated with MCD
(5 mM, titrated in preliminary experiments) for 30 min, washed, and incubated further with or without b2M-specific mAbs D1 or B2 (50 mg/ml). Apoptosis was
measured at 48 hr by the Annexin V binding assay. Immunoprecipitation using antibodies against D, MHC class I; E, Lyn; or F, PLCg2 in myeloma cells treated
with IgG1 or the mAbs (D1 or B2). Blotting antibodies used were against MHC class I, Lyn, Syk, and PLCg2 (D), MHC class I and Lyn (E), or MHC class I and PLCg2
(F). G: Western blot showing phosphorylated Lyn (pLyn) and pPLCg2 in myeloma cells after treatment with b2M-specific mAbs. Nonphosphorylated kinases
were also shown. Results obtained with D1 mAb on MM.1S and/or ARP-1 myeloma cells from one representative experiment out of four performed are shown.
Similar results are obtained with other tumor cell lines and primary myeloma cells. Error bars = SEM.days after the final injection of b2M-specific mAbs. Implanted
human bones from SCID-hu mice and organs including heart,
liver, kidney, lung, and spleen from A2-mice were removed for
histological examination. Treatment with the mAbs or IgG1 did
not change the body weight of the mice (Figure S5A) or cause
cell or tissue damage in marrow cells of the implanted human
bones, or in the murine organs that express human b2M/HLA-
A2molecules (Figure S5B).We also examinedmyeloma-bearing
SCIDmice after completingmAb treatment and found no normal
tissue damage (data not shown).
In vitro and in vivo experiments were conducted to examine
the possibility that b2M-specific mAbs, by binding to and block-
ing MHC class I on normal cells, trigger NK-mediated killing of
the cells. PBMCs freshly isolated from healthy donors were
labeled with chromium 51 (51Cr), washed, and incubated with
or without mAb D1 or IgG1 for 30 min, followed by incubation
with purified, autologous NK cells for 4 hr. As shown in Fig-
ure S5C, NK cells did not lyse PBMCs pretreated with or without
D1 mAb or IgG1. However, these NK cells efficiently killed K562
cells. Furthermore, no cell apoptosis or tissue damage was ob-
served after immunohistochemical examination of the human
marrow cells from SCID-hu mice, in which D1 mAb and subse-
quently purified human NK cells were injected directly into the
implanted human bones (data not shown). These studies further
confirmed our results that b2M-specific mAbs may be less toxic
or nontoxic to normal human cells and tissues in vivo.302In vivo validation of the mechanisms underlying
apoptosis of tumor cells induced by b2M-specific mAbs
To confirm whether b2M-specific mAbs utilized the samemech-
anisms of apoptosis induction in tumor cells in vivo, tumor-
bearing mice were sacrificed after treatment, and tumors were
removed for immunohistochemical analysis. As shown in Fig-
ure 7, injections of b2M-specific mAbs led to upregulation and
activation of pJNK, cleavage of caspase-9 and caspase-3
(data not shown), and induction of apoptosis of myeloma cells
detected by in situ TUNEL assay. Injection of the JNK inhibitor
(R10 mM) around the tumors prior to each mAb treatment not
only inhibited b2M-specific mAb-induced JNK phosphorylation,
caspase-9 cleavage, and induction of apoptosis (Figure 7A), but
also abrogated the therapeutic efficacy of the mAbs on estab-
lished myeloma in SCID mice (Figure 7B). The TUNEL assay
was also used to confirm induction of apoptosis of other tumors
in SCID mice (Figure S6). Hence, these results validated the
mechanisms of b2M-specific mAb-induced signaling and apo-
ptosis in tumor cells.
Discussion
This study describes a finding that mAbs against b2M induced
apoptosis in all tested surface b2M/MHC class I-positive tumor
cells of human hematological malignancies, including estab-
lished cell lines and primary tumor cells isolated from patients.CANCER CELL OCTOBER 2006
A R T I C L EFigure 6. In vivo therapeutic effects of b2M-specific mAbs on established human myeloma and other hematological tumors in SCID or SCID-hu mouse models
SCID mice were xenografted subcutaneously with ARP-1, MM.1S, CA-46, Granta 519, or KG1 cells, and tumor burdens were monitored as tumor volumes (up-
per panels;A for myeloma cells, and B for other tumor cells). Mice received intraperitoneal injections (every 3 days for a total of four injections) of 250 ml ascites
containing about 500 mg D1 b2M-specific mAb or 500 mg mouse IgG1, or an equal volume of PBS. Survival of SCID mice is shown in lower panels; A for myeloma
cells, and B for other tumor cells (survival times: b2M-specific mAb group versus PBS or IgG1 groups: p < 0.01 in all models). Results from one representative ex-
periment with five mice per group of three performed using D1 mAb are shown. Similar results are obtained with another b2M-specific mAb (E6) on these two
myeloma cell lines. In SCID-hu mice (six mice per group), primary myeloma cells from patients (n = 3) were directly injected into implanted human bones, and
tumor growth was monitored as levels of circulating human M-protein or its light chain (A, far right; Primary MM). Mice received the same treatments as SCID.
Note: because primary myeloma cells only grow in implanted human bone and not in murine bone marrow or other organs, these mice usually do not de-
velop systemic symptoms and become moribund; therefore, no death data were available. *p < 0.05; **p < 0.01. Error bars = SEM.These mAbs also exhibited a strong tumoricidal and therapeutic
activity in vivo in xenograft mousemodels of myeloma (including
primarymyeloma cells in SCID-hu host), lymphomas, and leuke-
mia, without damagingmarrow hematopoietic cells of implanted
human bone or murine organs that express human b2M/HLA-A2
molecules. The mAbs induced apoptosis in a caspase-depen-
dent manner, in the absence of secondary cross-linking andCANCER CELL OCTOBER 2006immunological effector mechanisms such as complement and
ADCC. Therefore, b2M-specificmAbs offer a potential therapeu-
tic approach to hematological malignancies.
MHC class I and II molecules may be unique targets for induc-
tion of apoptosis. Bothmurine and fully human HLA-DR-specific
mAbs have been shown to inhibit growth and induce pro-
grammed death of MHC class II-bearing tumor cells (Nagy303
A R T I C L EFigure 7. In vivo validation of signaling and apoptosis mechanisms
A: Myeloma (MM.1S)-bearing mice were treated as previously indicated, sacrificed, and had tumors removed for immunohistochemical staining for phos-
phorylated JNK (pJNK), cleaved caspase-9 (cCaspase-9), and apoptotic cells by in situ TUNEL assay. Shown are staining of tumors after one treatment
with intraperitoneal injection of the mAbs. In some experiments, JNK inhibitor (JNK inhibitor II, 20 mM) was injected around the tumors before injecting the
mAbs. Scale bar, 20 mM. B: Effect of the JNK inhibitor in abrogating the therapeutic efficacy of b2M mAbs on established myeloma (MM.1S) in SCID mice.
PBS contained DMSO. It is evident that the JNK inhibitor at R10 mM was effective. Representative results of three experiments are shown. The same results
were also obtained with other tumor cells lines in SCID mice. Error bars = SEM.et al., 2002; Vaickus et al., 1989; Vidovic and Toral, 1998). These
mAbs were shown to be selective to activated or tumor-trans-
formed cells, and caused no long-lasting hematological toxicity
in primates (Nagy et al., 2002). Consequently, HLA-DR-specific
mAbs are currently being evaluated for the treatment of lym-
phoid malignancies. On the other hand, ligation of MHC class I
molecules on T and B lymphocytes triggered signal transduc-
tion, which induced responses ranging from anergy and apopto-
sis to cell proliferation and IL-2 production (Skov, 1998). These
data suggested that MHC class I molecules alone or in associ-
ation with other signal transducing molecules may be involved
in regulation and fine-tuning of immune responses. By second-
ary cross-linking via plastic immobilization (Skov et al., 1997;
Woodle et al., 1997) or use of secondary antibodies (Pedersen
et al., 1999), these MHC class I-specific mAbs, including 5H7,
induced apoptosis in B cell lymphoma and other cells in vitro.
Soluble 5H7 also inhibited T cell proliferation (Smith et al.,
1994). In contrast, mAbs specific for b2M in this study induced
tumor apoptosis without the need for secondary cross-linking,
and were therefore effective in killing tumor cells in vivo.
Previous studies have indicated that b2M/MHC class I can
serve as important signal-transducing molecules (Skov, 1998).
We show here that b2M-specific mAbs targeted surface b2M/
MHC class I, and binding of the mAbs to tumor cells resulted
in internalization and downmodulation of these molecules and
induction of apoptosis of the cells. This finding is supported
by siRNA experiments in which knockdown of surface b2M
and MHC class I molecules abrogated induction of apoptosis
of tumor cells induced by the mAbs. We also showed that
b2M-specific mAb binding to surface b2M/MHC class I mole-
cules activated the JNK signaling pathway and inhibited PI3K/
Akt and ERK pathways; cleaved capase-9, -3, -7, and PARP;
upregulated Bad and Bax protein expression; induced phos-
phorylation of Bcl-2 and decreased phosphorylation of Bad;
and released cytochrome c into the cytosol. Consistent with
these results, it has been shown that JNK activation can lead
to phosphorylation of Bcl-2 and upregulation of Bax protein304expression (Maundrell et al., 1997). Phosphorylation of Bcl-2
blocked the antiapoptotic activity of this protein, partly due to
a loss of ability to bind to Bax (Srivastava et al., 1998), which
increased the permeability of mitochondria (Tsujimoto, 1998).
On the other hand, inhibition of the PI3K/Akt and ERK path-
ways abrogated the phosphorylation of Bad and increased its
binding or dimerization with Bcl-xL, which in turn blocked the
antiapoptotic activity of Bcl-xL and again led to increased per-
meability of mitochondria (Franke et al., 1997, 2003). Conse-
quently, cytochrome c was released into cytosol, caspase-9
cascade activated, and apoptosis induced. In vivo experiments
using tumor-SCID mouse models validated these findings.
In this study, we elucidated the mechanisms underlying b2M-
specific mAb-induced apoptosis and selectivity toward tumor
cells, and identified the signalingmolecules betweenMHC class
I and the downstream JNK, PI3K/Akt, and ERK kinases. We
showed that following treatment of myeloma cells with the
mAbs, MHC class I relocated to lipid rafts, where they recruited
and activated kinases Lyn and PLCg2. Indeed, both Lyn and
PLCg2 were shown to be physically associated with MHC class
I and phosphorylated in myeloma cells (Figure 5). Furthermore,
the importance of lipid rafts in myeloma cell apoptosis was con-
firmed by treatment with lipid raft-disrupting agent MCD (Ander-
son et al., 2000). Activation or phosphorylation of Lyn and
PLCg2 led to JNK activation and inhibition of PI3K/Akt and
ERK pathways (Kurosaki, 1999; Shangary et al., 2003), which
in turn induced apoptosis (Franke et al., 1997; 2003). Also, there
was a differential expression of b2M/MHC class I molecules by
normal and cancer cells (Figure 3). Together with our findings
in normal B cells that Lyn was not associated with lipid rafts
and b2M-specific mAbs did not trigger MHC class I relocation
to the rafts, and that JNK, PI3K/Akt, and ERK activities remained
unchanged after the mAb treatment, these data provide a plau-
sible explanation for the selectivity and sensitivity of b2M-spe-
cific mAb-mediated apoptosis of normal versus malignant cells.
Concerns may be raised with future clinical application of
these mAbs, such as the possibility of NK cell killing of normalCANCER CELL OCTOBER 2006
A R T I C L Ecells due to potential blockade of cell surface MHC class I mol-
ecules by the mAbs. We investigated this possibility by examin-
ing human NK cell cytolysis of normal cells in the presence or
absence of the mAbs in both in vitro and in vivo situations,
and found no killing or damage to human cells or tissues, even
though the NK cells were cytolytic to their target K562 cells. An-
other concern is the possible formation of damaging immune
complexes formed by soluble b2M binding the mAbs, and if
they are present, whether our animal models could capture
the complexes. We examined sera of myeloma-bearing mice
and found that after myeloma was established in SCID or
SCID-hu mice, circulating human b2M levels could reach
3 mg/ml, which is equal to levels seen in about 50% of newly di-
agnosed myeloma patients. Yet, these mAbs were therapeutic
and caused no damage to normal tissues in these mice. Thus,
to a large extent, the animal models represent human disease
and are well suited for the preclinical studies. Other barriers
for future clinical application may include blocking effects of sol-
uble and cell-expressing b2M, safety and toxicity of the mAbs,
and generation of anti-mouse IgG. These issues warrant further
studies to compare SCID and HLA-A2-transgenic SCID mice (in
which every tissue and all cells express human b2M) to examine
the efficacy of the mAbs to kill tumor cells in these hosts, use
nonhuman primates for safety and toxicity studies, and generate
and examine chimeric or humanized mAbs against b2M for their
capacity to induce apoptosis of tumor cells. Furthermore, wewill
also use in vitro assays and mouse models to examine the cyto-
lytic effects of mAb-mediated ADCC and CDC on tumor and
normal cells.
In summary, we show for the first time that b2M-specificmAbs
alone are tumoricidal to tumor cells of many hematological ma-
lignancies. These mAbs selectively induced apoptosis of tumor
cells in vitro and eradicated established tumors in xenograft
mouse models of myeloma, including primary myeloma cells
and other hematological tumors. The mAbs induced cell death
via recruiting MHC class I molecules to lipid rafts, recruiting
and activating Lyn and PLCg2, in turn activating JNK and inhib-
iting PI3K/Akt and ERK, which then leads to compromised mito-
chondrial integrity, cytochrome c release, and activation of the
caspase-9 cascade. We anticipate that these mAbs may be
even more effective in the presence of immunological effectors
such as complement and NK cells.
Experimental procedures
Experimental animals
Balb/c mice and CB.17 SCID mice were purchased from Harlan (Indianapo-
lis, IN), and human b2M/HLA-A2-transgenic C57BL/6 mice were obtained
from the Jackson Laboratory (Bar Harbor, ME). All mice were maintained in
American Association of Laboratory Animal Care-accredited facilities, and
studies were approved by the Institutional Animal Care and Use Committees
of the University of Arkansas for Medical Sciences and The University of
Texas M. D. Anderson Cancer Center.
Cell lines, primary tumor cells, and reagents
Human myeloma cell lines ARP-1 and ARK-RS were established at the
Arkansas Cancer Research Center from bone marrow aspirates of patients
with MM (Hardin et al., 1994), and MM.1S and MM.1R were kindly provided
by Dr. Steven Rosen of Northwestern University (Chicago, IL). The other
tumor cell lines were purchased fromATCC. Primarymyeloma cells were iso-
lated from bone marrow aspirates obtained from patients during a routine
clinic visit. CD138++myelomacells andCD56+NKcellswere isolated bymag-
netic-bead sorting (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).CANCER CELL OCTOBER 2006Purified human b2M andmouse IgG and IgG1 were purchased from Sigma
(St. Louis, MO). Monoclonal antibodies against b2M (clone B2) and HLA-ABC
(cloneW6/32) were purchased fromSerotec Ltd., andmAb against HLA-ABC
(clone LY5.1) was purchased from Acris Antibodies GmbH (Hiddenhausen,
Germany).
Generation of D1 and E6 monoclonal antibodies
Female Balb/c mice were immunized with purified human b2M protein. Lym-
phocytes from spleens were fused with SP2/0 myeloma cells, and positive
hybridomas were screened against b2M by ELISA. Large-scale antibody pro-
duction of selected clones, such as D1 and E6 (both are IgG1), was achieved
by purifying mAbs from culture media using a protein G column (Amersham
Biosciences, Piscataway, NJ) or by intraperitoneal injection of 2 3 106 hy-
bridoma cells into Balb/c mice to produce ascites. Isotyping of mAbs was
performed using a kit purchased from Serotec Ltd.
Generation of osteoclasts and coculture with myeloma cells
The method has been described previously (Yaccoby et al., 2004). PBMCs
were cultured in 24-well plates in a-MEM medium supplemented with 10%
fetal calf serum, antibiotics, RANK ligand (50 ng/ml), human M-CSF
(25 ng/ml), and 10 nM dexamethasone for 10 to 14 days to generate tar-
trate-resistant acid phosphatase (TRAP)+ and vitronectin receptor+ osteo-
clasts. Before coculture, osteoclasts were washed, and freshly isolated my-
eloma plasma cells from patients (0.53 106 cells/ml) were added to the wells
and cocultured with osteoclasts, with or without the addition of b2M-specific
mAbs. At the end of the studies, myeloma cells were detached from osteo-
clasts, and both myeloma and osteoclasts were subjected to analysis.
Apoptosis assays, caspase inhibitor, RNA interference,
flow cytometry analysis of cell surface antigens, histology,
immunohistochemistry, immunofluorescence analyses,
immunoprecipitation, western blotting, and cytotoxicity assay
See Supplemental Experimental Procedures.
Isolation of lipid rafts
The Caveolae/Raft Isolation Kit (Sigma) was used to isolate lipid rafts as low
density, detergent-resistant membrane fractions by sucrose density gradient
centrifugation using 1% Triton-X-100 (Rietveld et al., 1999). Briefly, 5 3 107
cells were lysed for 30 min in ice-cold lysis buffer. Cell lysates were mixed
with OptiPrep to 35%, placed at the bottom of the ultracentrifuge tube, over-
laid with four layers of 30% to 0% OptiPrep, and centrifuged at 200,000 3 g
using a TFT 65.13 rotor (Kontron Instruments) for 4 hr at 4C. Nine fractions
(1 ml each) were collected from the top to the bottom of the gradients. The
lipid rafts determined with a caveolin-1-specific antibody were found in frac-
tions 2 to 5.
In vivo antitumor activity of b2M-specific monoclonal antibodies
Six- to eight-week-old female CB.17 SCID mice were subcutaneously inoc-
ulated in the right flank with 13 106 ARP-1, 23 106MM.1Smyeloma, 53 106
CA46 Burkitt’s lymphoma, Granta 519 mantle cell lymphoma, or KG1 acute
myelogenous leukemia cells in 50 ml RPMI-1640 medium. Three to four
weeks later, when palpable tumors (R5 mm in diameter) developed, mice
(n = 5 for all groups) were treated with either subcutaneous (around tumors)
injections of 200 mg purified D1 b2M-specific mAb (or 100 ml ascites contain-
ing about 200 mg D1) or intraperitoneal injections of 250 ml ascites containing
the mAb every 3 days for a total of four injections. Control mice received
equal amounts of mouse IgG1 or PBS injected the same way as the mAb.
To deplete murine NK cells, mice were injected intraperitoneally with 25 ml
of anti-asialo GM1 antiserum (Wako Chemicals, Richmond, VA) 2 days be-
fore mAb treatment. This was repeated each week throughout the experi-
ment in all mice. Tumor size was measured every 3 days in two dimensions
using a caliper, and tumor volume (mm3) was calculated as 4p/3 3 (tumor
width/2)23 (tumor length/2) (LeBlanc et al., 2002). Serum was also collected
from mice twice a week and used for detection by ELISA of myeloma-
secreted M-proteins (human immunoglobulins) or their light chains. Mice
were humanely sacrificed when moribund or when subcutaneous tumors
reached 15 mm in diameter. Survival was evaluated from the day of tumor
inoculation until death.
SCID-hu mouse model was established in CB.17 SCID mice as described
before (Yaccoby et al., 1998). Freshly isolated primary myeloma cells305
A R T I C L E(1 3 106/mouse) from patients were directly injected to implanted human
bones, and once myeloma was established (circulating human M-proteins
or their light chains reaching >50 mg/ml), treatment began, which was the
same as for SCID mice. In some experiments, 100 mg of D1 mAb or IgG1
was injected directly into implanted human bones that contained no tumor
cells, followed by injection of purified human NK cells (2 3 106 cells), and
the injections were repeated once again 3 days later. Mice were sacrificed
3 days after the final injection and human bones were removed for immuno-
histochemical examination.
Statistical analysis
All data are shown as means 6 SEM. The Student’s t test was used to com-
pare various experimental groups. In mouse experiments, overall survival
was measured using the Kaplan-Meier method, and the log-rank test was
used for group comparison. Significance was set at p < 0.05.
Supplemental data
The Supplemental Data for this article can be found online at http://www.
cancercell.org/cgi/content/full/10/4/295/DC1/.
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